NOVO NORDISK FACES 'SHOW ME' MOMENT TO BOOST WEGOVY GROWTH AFTER US COPYCAT BAN
https://media.zenfs.com/en/reuters-finance.com/ce9165e3a9f18cb37fec90deb8859ae2
✍️ Novo Nordisk's weight loss drug Wegovy has seen an increase in prescriptions since a US FDA ban on copycat versions took effect, but the company needs to show robust growth to boost market confidence.
👉 New Wegovy prescriptions have increased by 33% since the FDA ban on compounded versions took effect 👉 Total Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly's Zepbound 👉 Novo Nordisk has rolled out new tactics to bring patients back, including a limited-time discount and better coverage from insurer CVS Health 👉 Analysts are skeptical about the effectiveness of these moves and expect Novo Nordisk to reduce or narrow its full-year guidance ranges
-- #MaggieFick #LarsFruergaardJorgensen #EmilyField #KerryHolford #MarcusMorris-Eyton #LONDON #Copenhagen #Bengalaru #health
Loading quoted post…
